Ptct stock company

Therapeutics (NasdaqGS:PTCT) - Share price, News ... PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. PTCT - PTC Therapeutics Inc. • BioPharmCatalyst

PTCT -- Is Its Stock Price A Worthy Investment? Learn More. PTCT Stock Summary. With a price/sales ratio of 10.69, Ptc Therapeutics Inc has a higher such ratio than 89.05% of stocks in our set. With a year-over-year growth in debt of 107.49%, Ptc Therapeutics Inc's debt growth rate surpasses 87.12% of about US stocks. PTC Therapeutics A Science-Led, Patient-Centric Approach to Treating Rare Diseases

PTCT Stock Price | PTC Therapeutics Inc. Stock Quote (U.S ...

PTCT -- Is Its Stock Price A Worthy Investment? Learn More. PTCT Stock Summary. With a price/sales ratio of 10.69, Ptc Therapeutics Inc has a higher such ratio than 89.05% of stocks in our set. With a year-over-year growth in debt of 107.49%, Ptc Therapeutics Inc's debt growth rate surpasses 87.12% of about US stocks. PTC Therapeutics A Science-Led, Patient-Centric Approach to Treating Rare Diseases PTCT.OQ - PTC Therapeutics, Inc. Profile | Reuters About PTC Therapeutics, Inc. PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in

PTCT - Ptc Therapeutics News - Barchart.com

The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product  Company Rating. What our community thinks about PTC Therapeutics. CAPS Rating 2 out of 5. 26 Outperform. 15 Underperform. CAPS All Stars. 7 Outperform. View the latest PTC Therapeutics Inc. (PTCT) stock price, news, historical charts, and Full Year 2019 Financial Results and Provides a Corporate Update. Public · Traded as · NASDAQ: PTCT · Russell 2000 Component. Industry, Pharmaceuticals. Headquarters. South Plainfield, New Jersey. ,. United States. Website, ptcbio.com. PTC Therapeutics is a US pharmaceutical company focused on the development of orally 

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates. PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

View PTC Therapeutics, Inc. PTCT investment & stock information. Get the latest PTC Therapeutics, Inc. PTCT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Questions Remain, But Analysts Stay Bullish: IAMGOLD ...

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates. PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? PTCT Stock Price Quote & News - PTC Therapeutics | Robinhood PTC Therapeutics, Inc. Common Stock, also called PTC Therapeutics, is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. Read More It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, … PTC Therapeutics, Inc. Common Stock (PTCT) Real-Time Stock ...

PTCT PTC Therapeutics, Inc. Stock Quote Is PTC Therapeutics, Inc. (PTCT) A Good Stock To Buy ? The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop PTCT May 15th Options Begin Trading | Nasdaq